About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.

Early Versus Delayed Enteral Feeding to Treat People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN Study)

Clinicaltrials.gov identifier NCT00883948

Recruitment Status Completed

First Posted April 20, 2009

Last update posted April 13, 2016

Study Description

Brief summary:

Acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) are medical conditions that occur when there is severe inflammation and increased fluids in both lungs, making it difficult for the lungs to function properly. Hospital treatment for a person with ALI/ARDS often includes the use of a breathing machine, or ventilator, until the person is able to breathe without assistance. Initiating proper nutrition through a feeding tube early in a person's hospital stay may help to improve recovery, but the optimal timing, composition, and amount of feeding treatments remain unknown. This study will evaluate whether early or delayed full-calorie feeding through a feeding tube is more effective in reducing recovery time and increasing survival rates in people with ALI/ARDS.

  • Condition or Disease:Respiratory Distress Syndrome, Adult
  • Intervention/Treatment: Behavioral: Minimal (Trophic) Feeding
    Behavioral: Full Feeding
  • Phase: Phase 3
Detailed Description

ALI/ARDS involves extensive inflammation in the lungs that can lead to rapid respiratory failure. These conditions are most commonly caused by pneumonia, generalized infection, or severe trauma to the lungs, but can also be less commonly caused by smoke or salt water inhalation, drug overdose, or shock. For some people, ALI/ARDS resolves without treatment, but many severe cases result in hospitalization in the intensive care unit (ICU), where 30% to 40% of cases end in mortality. Current treatments for ALI/ARDS include assisted breathing with a ventilator, supportive care, and management of the underlying causes. Enteral feeding, in which patients receive nutrition through a feeding tube, plays an important role in treatment, too. Some recent studies have shown that enteral feeding initiated soon after a patient begins assisted breathing is associated with a shorter hospital stay and a better chance of survival than delayed enteral feeding. However, other studies have shown the opposite, and studies on optimal feeding volume and composition have shown conflicting results. This study will evaluate the effects of early versus delayed full-calorie enteral feeding on mortality, ventilator-free days, ICU-free days, and organ failure in people with ALI/ARDS. Upon admission to the ICU, a dietary evaluation will be done on each participant to determine goal, or full-calorie, feeding rates, which will be based on body weight and daily energy consumption. Participants will also undergo baseline assessments and procedures, which will include vital sign measurements, blood draws, a frontal chest radiograph, ventilator settings, and placement of a feeding tube. Participants will be randomly assigned to receive initial enteral feedings that are either minimal (trophic) or full-calorie. All participants will begin enteral feeding within 6 hours of treatment assignment. Participants assigned to initial minimal enteral feedings will receive feedings at 10 cubic centimeters (cc) per hour, to be continued at this rate for 144 hours, provided that the participant remains on the ventilator. After the 144 hours, the feeding rate will be advanced to full-calorie rates. Participants assigned to initial full-calorie enteral feedings will receive feedings at 25 cc per hour, and the feeding rate will be increased by 25 cc per hour every 6 hours until the goal rate is reached. During enteral feedings, gastric residual volumes (GRVs) will be checked every 6 to 12 hours to assure acceptable levels. Participants will complete enteral feedings upon hospital discharge, Day 28 of treatment, death, or ability to achieve 48 hours of unassisted breathing. Blood pressure, heart rate, ventilation settings, and various blood factors will be measured during treatment. Phone-based follow-up assessments will occur at Months 6 and 12 after ICU discharge and will include measurements of health-related quality of life; psychological, neurocognitive, and physical activity outcomes; healthcare utilization; and mortality.

Study Design
  • Study Type: Interventional
  • Actual Enrollment: 1000 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Prospective, Randomized, Multi-Center Trial of Initial Trophic Enteral Feeding Followed by Advancement to Full-Calorie Enteral Feeding vs. Early Advancement to Full-Calorie Enteral Feeding in Patients With Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)
  • Study Start Date: December 2007
  • Actual Primary Completion Date: March 2011
  • Actual Study Completion Date: May 2011
Arms and interventions
Arm Intervention/treatment
Experimental: 1
Participants will receive initial minimal (trophic) enteral feeding.
Behavioral: Minimal (Trophic) Feeding
Upon admission to the ICU, enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
Experimental: 2
Participants will receive initial full-calorie enteral feeding.
Behavioral: Full Feeding
Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
Outcome Measures
  • Primary Outcome Measures: 1. Number of ventilator-free days (VFD) [ Time Frame: Measured at Day 28 ]
  • 2. Mortality before hospital discharge, with unassisted breathing [ Time Frame: Measured at Days 60 and 90 ]
  • Secondary Outcome Measures: 1. Number of intensive care unit-free days [ Time Frame: Measured at Day 28 ]
  • 2. Number of organ failure-free days (liver, kidney, heart, central nervous system, and hematologic) [ Time Frame: Measured at Day 28 ]
  • 3. Incidence of ventilator-associated pneumonia [ Time Frame: Measured at Day 28 ]
  • 4. Number of days from first meeting criteria for weaning readiness to Day 28 [ Time Frame: Measured at Day 28 ]
  • 5. VFDs and mortality in participants with a partial pressure of oxygen in arterial blood (PaO2)/fraction of inspired oxygen (FIO2) less than or equal to 200 or with shock at the time of study entry [ Time Frame: Measured at Days 28 and 60, respectively ]
  • 6. Change in plasma and mini-bronchoalveolar lavage (BAL) levels of interleukin (IL)-6, IL-8, von Willebrand factor (VWF), surfactant protein D (SPD), and total protein concentrations [ Time Frame: Measured at Day 3 ]
  • 7. Health-related quality of life; healthcare utilization; and psychological, neurocognitive, and physical activity outcomes [ Time Frame: Measured at Months 6 and 12 ]
  • 8. Duration of survival after hospital discharge using the National Death Index [ Time Frame: Measured at Months 6 and 12 ]
Eligibility Criteria
  • Ages Eligible for Study: 13 Years and older (Child, Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Must meet the following three criteria within a 24-hour period of study entry: 1)
PaO2/FiO2 less than or equal to 300 (if altitude is more than 1000 meters, then
PaO2/FiO2 less than or equal to 300 x [barometric pressure/760]), 2) bilateral
infiltrates (patchy, diffuse, homogeneous, or asymmetric) consistent with pulmonary
edema on frontal chest radiograph, and 3) requirement for positive pressure
ventilation via endotracheal tube

- No clinical evidence of left-sided cardiac failure to account for bilateral pulmonary
infiltrates

- Intention of primary medical team to enterally feed the patient

- Undergoes enteral feeding within 48 hours of meeting other inclusion criteria

Exclusion Criteria:

- Neuromuscular disease that impairs ability to breathe without assistance, such as
cervical spinal cord injury at level C5 or higher, amyotrophic lateral sclerosis,
Guillain-Barré syndrome, or myasthenia gravis

- Pregnant or breastfeeding

- Severe chronic respiratory disease (more information about this criterion can be found
in the protocol)

- Burns on greater than 40% total body surface area

- Cancer or other irreversible disease or condition for which 6-month mortality is
estimated to be greater than 50% (more information about this criterion can be found
in the protocol)

- Allogeneic bone marrow transplant in the 5 years before study entry

- Patient, surrogate, or physician not committed to full support (exception: a patient
will not be excluded if he/she would receive all supportive care except for attempts
at resuscitation from cardiac arrest)

- Severe long-term liver disease (Child-Pugh score of 11 to 15)

- Diffuse alveolar hemorrhage from vasculitis

- Morbid obesity, defined as 1 kg/cm body weight

- Unwilling or unable to use the ARDS network 6 mL/kg PBW ventilation protocol

- Moribund patient not expected to survive 24 hours after study entry

- No intent to obtain central venous access for monitoring intravascular pressures

- More than 72 hours since mechanical ventilation initiated

- Refractory shock (more information about this criterion can be found in the protocol)

- Unable to obtain enteral access

- Presence of partial or complete mechanical bowel obstruction

- Presence of ischemia or infarction

- Current total parenteral nutrition (TPN) use or intent to use TPN within 7 days of
study entry

- Severe malnutrition with body mass index less than 18.5 or loss of more than 30% total
body weight in the 6 months before study entry

- Laparotomy expected within 7 days of study entry

- Unable to raise head of bed 30 to 45 degrees

- Short-bowel syndrome or absence of gastrointestinal tract

- Presence of high-output (greater than 500 cc/day) enterocutaneous fistula

- International normalized ratio greater than 5.0, platelet count less than 30,000/mm3,
or history of bleeding disorder

- Intracranial hemorrhage in the 1 month before study entry

- Allergy to enteral formula

- Requirement for, or physician insistence on, enteral formula supplemented with omega-3
fatty acids (e.g., Oxepa®, Impact®) or treatment with omega-3 fatty acid,
gamma-linolenic acid (GLA), or antioxidant supplementation

Contacts and Locations
Contacts
Locations
Show 39 Study Locations
Sponsors and Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Investigators

Study Chair: Arthur P. Wheeler, MD Vanderbilt University Medical Center

More Information
  • Responsible Party: National Heart, Lung, and Blood Institute (NHLBI)
  • ClinicalTrials.gov Identifier: NCT00883948 History of Changes
  • Other Study ID Numbers: 651, N01-HR056179, HSN268200536179C
  • First Posted: April 20, 2009 Key Record Dates
  • Last Update Posted: April 13, 2016
  • Last Verified: February 2012
  • Keywords provided by National Heart, Lung, and Blood Institute (NHLBI): Acute Lung Injury
    Acute Respiratory Distress Syndrome
    Feeding
    Critical Care
    Ventilator
  • Additional relevant MeSH terms: Respiratory Distress Syndrome, Newborn
    Respiratory Distress Syndrome, Adult
    Acute Lung Injury
    Lung Injury
    Syndrome